WO1993003714A3 - Method for treatment of metabolic disorders - Google Patents
Method for treatment of metabolic disorders Download PDFInfo
- Publication number
- WO1993003714A3 WO1993003714A3 PCT/US1992/006536 US9206536W WO9303714A3 WO 1993003714 A3 WO1993003714 A3 WO 1993003714A3 US 9206536 W US9206536 W US 9206536W WO 9303714 A3 WO9303714 A3 WO 9303714A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- metabolic disorders
- administering
- animal
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5504336A JPH06510760A (en) | 1991-08-27 | 1992-08-11 | Metabolic disorders and metabolic treatments |
AU24075/92A AU664710B2 (en) | 1991-08-27 | 1992-08-11 | A method for treatment of metabolic disorders |
EP92917697A EP0600973A1 (en) | 1991-08-27 | 1992-08-11 | A method for treatment of metabolic disorders and metabolism |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75005991A | 1991-08-27 | 1991-08-27 | |
US75056991A | 1991-08-27 | 1991-08-27 | |
US750,569 | 1991-08-27 | ||
US750,059 | 1991-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993003714A2 WO1993003714A2 (en) | 1993-03-04 |
WO1993003714A3 true WO1993003714A3 (en) | 1993-06-10 |
Family
ID=27115223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/006536 WO1993003714A2 (en) | 1991-08-27 | 1992-08-11 | Method for treatment of metabolic disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0600973A1 (en) |
JP (1) | JPH06510760A (en) |
AU (3) | AU664710B2 (en) |
CA (1) | CA2113817A1 (en) |
WO (1) | WO1993003714A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2706899A1 (en) * | 1993-06-22 | 1994-12-30 | Synthelabo | Pyrrole derivatives, their preparation and their therapeutic application |
EP0599697A1 (en) * | 1992-11-24 | 1994-06-01 | Synthelabo | Pyrrole derivatives, their preparation and application in therapy |
ATE222100T1 (en) * | 1993-10-21 | 2002-08-15 | Searle & Co | AMIDINO DERIVATIVES USEFUL AS NO SYNTHASE INHIBITORS |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5935927A (en) * | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
FR2719844B1 (en) * | 1994-05-10 | 1996-06-07 | Synthelabo | 5,6-dihydro-4h-thieno [3,4-c] pyrrole derivatives, their preparation and their therapeutic use. |
GB9511757D0 (en) * | 1995-05-19 | 1995-08-02 | Univ Strathclyde | Agents for reducing weight |
US5955617A (en) * | 1996-05-21 | 1999-09-21 | Pharmacia & Upjohn Company | Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
JP2002512954A (en) * | 1998-04-24 | 2002-05-08 | マイトコー | Compounds and methods for treating mitochondrial-related diseases |
CN1198803C (en) * | 1999-03-05 | 2005-04-27 | 第一三得利制药株式会社 | Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor |
WO2001003680A2 (en) * | 1999-07-09 | 2001-01-18 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
SE0004462D0 (en) | 2000-12-04 | 2000-12-04 | Pharmacia Ab | Novel method and use |
AU2002221222A1 (en) * | 2000-12-04 | 2002-06-18 | Biovitrum Ab | Novel method and use |
GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
US7541477B2 (en) | 2002-07-30 | 2009-06-02 | Banyu Pharmaceutical Co., Ltd. | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
ITRM20020625A1 (en) * | 2002-12-17 | 2004-06-18 | Sigma Tau Ind Farmaceuti | DERIVATIVES OF GUANIDINE VARIOUSLY REPLACED, THEIR USE AS MEDICATIONS WITH ANTI-DIABETIC AND / OR ANTIOBESITY ACTIVITY. |
US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JPWO2006061992A1 (en) * | 2004-12-10 | 2008-06-05 | 味の素株式会社 | Liver disease prevention / treatment composition |
CA2642429A1 (en) * | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
BRPI0620637A2 (en) | 2005-12-22 | 2011-11-16 | Neurochem Int Ltd | use of compounds in the preparation of medicaments for the prevention or treatment of diabetic nephropathy, complication of renal disorder and dyslipidemia, reduced serum lipid and uric acid levels, and increased creatinine clearance and renal function |
EP2058008B1 (en) * | 2006-08-11 | 2013-08-21 | National University Corporation Nagoya University | Anti-obesity agent and use thereof |
DE102007004781A1 (en) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent |
GB0800383D0 (en) * | 2008-01-10 | 2008-02-20 | Univ Strathclyde | Weight reducing compounds |
KR101912494B1 (en) * | 2012-10-18 | 2018-10-26 | 니신 쇼쿠힌 홀딩스 가부시키가이샤 | Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method |
GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
DK3164123T3 (en) | 2014-07-02 | 2020-08-03 | Inflectis Bioscience | Novel uses of benzylideneguanidine derivatives in the treatment of proteopathies |
DE102016125414A1 (en) * | 2016-12-22 | 2018-06-28 | Bitop Ag | Composition containing N-acetyldiaminobutyric acid |
GB2609003A (en) * | 2021-07-15 | 2023-01-25 | Univ Nottingham Trent | Compounds and pharmaceutical compositions for the treatment of metabolic disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2673381B2 (en) * | 1990-02-23 | 1997-11-05 | 持田製薬 株式会社 | Pre-diabetes treatment agent and / or lipid lowering agent |
AU7316591A (en) * | 1990-02-28 | 1991-09-18 | Upjohn Company, The | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders |
-
1992
- 1992-08-11 CA CA002113817A patent/CA2113817A1/en not_active Abandoned
- 1992-08-11 JP JP5504336A patent/JPH06510760A/en active Pending
- 1992-08-11 EP EP92917697A patent/EP0600973A1/en not_active Withdrawn
- 1992-08-11 WO PCT/US1992/006536 patent/WO1993003714A2/en not_active Application Discontinuation
- 1992-08-11 AU AU24075/92A patent/AU664710B2/en not_active Ceased
-
1995
- 1995-09-14 AU AU30614/95A patent/AU3061495A/en not_active Abandoned
- 1995-09-14 AU AU30615/95A patent/AU3061595A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
CHEM. PHARM. BULL. vol. 18, no. 8, 1970, pages 1636 - 1642 FUJIHIRA,E., ET AL 'EFFECT OF LONG-TERM FEEDING OF TAURINE IN HEREDITARY HYPERGLYCEMIC OBESE MICE' * |
Also Published As
Publication number | Publication date |
---|---|
JPH06510760A (en) | 1994-12-01 |
AU3061595A (en) | 1995-11-09 |
AU2407592A (en) | 1993-03-16 |
AU664710B2 (en) | 1995-11-30 |
WO1993003714A2 (en) | 1993-03-04 |
EP0600973A1 (en) | 1994-06-15 |
CA2113817A1 (en) | 1993-02-04 |
AU3061495A (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993003714A3 (en) | Method for treatment of metabolic disorders | |
CA2045885A1 (en) | Inhibition of mammalian muscle wasting and protein degradation by tetracyclines | |
AU609664B1 (en) | A method of treating premature ejaculation using sertraline | |
HK129393A (en) | Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus | |
CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
CA2204616A1 (en) | Ppar gamma antagonists for treating obesity | |
PL306590A1 (en) | Substituted heterocyclic carboxylamides, method obtaining them and their application as therapeutic agents | |
HUT59313A (en) | Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions | |
WO1996015784A3 (en) | 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance | |
CA2015838A1 (en) | Method of topically treating acne vulgaris | |
CA2108903A1 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
WO1992019211A3 (en) | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same | |
IL102807A0 (en) | Therapeutic compounds | |
AU1302388A (en) | Method of treating anxiety with tetrahydrobenz(c,d)indole-6- carboxamides | |
RU94045271A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition | |
GB9108629D0 (en) | Heterocyclic pharmaceutical compounds,preparation and use | |
CA2120319A1 (en) | Pharmaceutical for the treatment of skin disorders | |
AU1173597A (en) | Agent for prophylaxis and treatment of diabetic complications | |
NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
EP0768083A3 (en) | The use of sertraline to treat post myocardial infarction patients | |
AU1855088A (en) | Treating agent for heart failure | |
HU905683D0 (en) | The treatment of drug dependence by using sertraline | |
HU9203052D0 (en) | Method for treatment of hypertension | |
GEP20032956B (en) | Miticide Composition | |
WO1997005875A3 (en) | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2113817 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992917697 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992917697 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 469716 Country of ref document: US Date of ref document: 19950606 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992917697 Country of ref document: EP |